
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Recipient : Formycon
Deal Size : Undisclosed
Deal Type : Partnership
Horus Pharma Becomes Additional Commercialization Partner for Formycon's Eylea Biosimilar
Details : The partnership aims for the commercialization of Formycon's Eylea biosimilar FYB203, under the brand name Baiama, in selected European countries.
Product Name : Baiama
Product Type : Protein
Upfront Cash : Undisclosed
September 17, 2025
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Recipient : Formycon
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fluocinolone Acetonide
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Alimera Sciences
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Alimera and Horus have agreed to increase the commercialization efforts for ILUVIEN (fluocinolone acetonide) for both diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in Euro...
Product Name : Iluvien
Product Type : Steroid
Upfront Cash : Undisclosed
April 03, 2023
Lead Product(s) : Fluocinolone Acetonide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Alimera Sciences
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Barcimiant
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Genuine Research Center, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Barcimiant is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 16, 2021
Lead Product(s) : Barcimiant
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Genuine Research Center, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rivaroxaban
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Genuine Research Center, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rivaroxaban is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 06, 2017
Lead Product(s) : Rivaroxaban
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Genuine Research Center, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable
